Association of Dopamine Agonist Use With Impulse Control Disorders in Parkinson Disease

Daniel Weintraub, MD; Andrew D. Siderowf, MD, MSCE; Marc N. Potenza, MD, PhD; Joseph Goveas, MD; Knashawn H. Morales, ScD; John E. Duda, MD; Paul J. Moberg, PhD; Matthew B. Stern, MD

**Objective:** To determine the frequency and correlates of impulse control disorders (ICDs) in Parkinson disease (PD).

**Design:** An unstructured screening interview for ICDs (compulsive gambling, buying, and sexual behavior) followed by a telephone-administered structured interview for screen-positive patients.

**Setting:** Two university-affiliated movement disorders centers.

**Participants:** A convenience sample of 272 patients with idiopathic PD who were screened for psychiatric complications.

**Main Outcome Measures:** Presence of compulsive gambling, buying, or sexual behavior as assessed by the Minnesota Impulsive Disorders Interview.

**Results:** Eighteen patients (6.6%) with PD met criteria for an ICD at some point during the course of PD, including 11 (4.0%) with an active ICD. Compulsive gambling and compulsive sexual behavior were equally common. In a multivariate model, treatment with a dopamine agonist (P = .01) and a history of ICD symptoms prior to PD onset (P = .02) predicted current ICD. There were no differences between the dopamine agonists in their association with ICDs (P = .21), and daily doses of dopamine agonists were higher in patients with an ICD than in dopamine agonist–treated patients without an ICD (P < .001).

**Conclusions:** Patients with PD treated with a dopamine agonist should be made aware of the risk of developing an ICD and monitored clinically. Because dopamine agonists are increasingly being used for other indications, future research should assess the dopamine agonist–associated risk for ICDs in other populations.

Arch Neurol. 2006;63:969-973

**Recent Observational Studies** suggest that impulse control disorders (ICDs), particularly pathological gambling, may have increased frequency in Parkinson disease (PD). Impulse control disorders constitute a group of psychiatric disorders in DSM-IV-TR, their essential feature being a failure to resist an impulse, drive, or temptation to perform an act that is harmful to the person or to others. Other ICDs without formal diagnostic criteria in DSM-IV-TR include compulsive sexual behavior and compulsive buying.

Although there are case reports of levodopa-induced ICDs in PD, recent case series have implicated treatment with dopamine agonists as a more frequent cause of pathological gambling. Driver-Dunckley et al identified 9 patients (0.5% of clinic sample) with a documentation of pathological gambling, 8 of whom were treated with pramipexole and 1 with pergolide mesylate. In another case series, all 11 patients with PD identified as meeting DSM-IV criteria for pathological gambling were taking a dopamine agonist, 9 of whom were taking pramipexole and 2, ropinirole hydrochloride. Regarding other ICDs in PD, in a series of 15 patients with either PD or multiple system atrophy and compulsive hypersexuality, dopamine agonist treatment was implicated as the cause of the behavior in 14 cases. There have also been anecdotal reports of compulsive buying in association with dopamine replacement therapies.

We report the results of a screening and assessment study of ICDs in PD investigating the: (1) frequencies of compulsive buying, gambling, and sexual behaviors; (2) demographic and clinical correlates of the aforementioned ICDs; and (3) association between ICDs and dopamine agonist use. We hypothesized that ICDs in PD are associated with dopamine agonist treatment and that this association is dose dependent and similar across the entire class of dopamine agonists.
The study population was outpatients diagnosed with idiopathic PD, predominantly of mild to moderate severity, confirmed by a movement disorders specialist. Subjects were established patients at 1 of 2 movement disorders centers (either the University of Pennsylvania or the Philadelphia Veterans Affairs Medical Center) and were thought to represent a cross-section of the clinics’ populations, save the exclusion of patients unable to provide informed consent because of cognitive impairment. Participants completed a psychiatric screening interview as part of a study of the frequency and correlates of depression in PD. The institutional review boards at the 2 institutions approved the study, and written informed consent was obtained from all subjects.

**DATA COLLECTION AND MEASURES**

Patients were screened between July 2004 and June 2005. Movement disorders professionals were instructed to refer any willing patient with PD, without regard for their psychiatric status (eg, no patient was referred for having an ICD), for the screening interview at the conclusion of his or her clinic appointment.

Two trained research assistants administered the screening battery, which included open-ended questions about the existence (lifetime, anywhere during PD, and currently) of recurrent compulsive buying, gambling, or sexual behaviors. Subjects were also administered the 15-item Geriatric Depression Scale and the Mini-Mental State Examination as part of the screening process.

Those who screened positive for an ICD during the course of PD were contacted by telephone in August or September 2005 by 1 of us (D.W. or J.G.) and administered a modified Minnesota Impulsive Disorders Interview (MIDI), which includes queries for the presence of clinically significant compulsive gambling, sexual, and buying behaviors. Patients were instructed to answer the questions based on their state at the time they were symptomatic. Impulse control disorders were defined as answering in the affirmative to 1 (compulsive sexual behavior and compulsive shopping) or 2 (compulsive gambling) gateway questions plus an affirmative answer to 1 or more of the remaining questions of the relevant ICD module of the MIDI. The same threshold has been used to define problem gambling in other studies. The MIDI was administered to confirm the presence of ICDs during the course of PD only (ie, not applied to pre-PD-onset ICD symptoms).

To verify data accuracy, the study primary investigator (D.W.) reviewed the medical records of all patients identified as having an ICD some time during the course of PD. For patients with an ICD at some time during the course of PD but who were no longer symptomatic, medical records were reviewed and medications recorded for the period when they were most symptomatic.

For analytic purposes, a levodopa-equivalent daily dose (LEDD) was calculated on the basis of the following formula, similar to that previously reported:

100 mg of levodopa=130 mg of controlled-release levodopa=70 mg of levodopa + catechol-O-methyl-transferase inhibitor=1 mg of pergolide=1 mg of pramipexole=5 mg of ropinirole.

Other PD medications (eg, anticholinergics and monoamine oxidase inhibitors) that have not been associated with ICDs were not included in the analyses. The LEDDs were calculated both for dopamine agonists only (dopamine agonist LEDD) and for dopamine agonists + levodopa (total LEDD).

To probe for possible risk factors for the development of ICDs in PD, data were obtained for factors that have been reported to be associated with ICDs in PD (type and dose of dopamine replacement therapy, disease duration, age, and sex) or that were factors of interest (history of ICD behavior, global cognition, educational level, and marital status). For the purposes of this study, dopamine agonists were considered to be pramipexole, ropinirole, and pergolide. Amantadine hydrochloride, which has an unclear mechanism of action but has some dopamine agonist properties, was considered separately, and no patient was prescribed bromocriptine mesylate or apomorphine hydrochloride. Reliable data were not available for the duration of treatment with dopamine replacement therapies. All clinical and demographic data were obtained directly from the patient during the screening interview and, when possible, verified by medical record review.

**RESULTS**

**PATIENT CHARACTERISTICS**

Two hundred seventy-two patients, ranging in age from 35 to 91 years, completed the screening process. The use of the Philadelphia Veterans Affairs Medical Center as a site led to a preponderance of men in the study population. One half of subjects (137 [50.4%] of 272) were taking a dopamine agonist at screening. For patients taking a dopamine agonist at screening, there were no between-group differences in mean dopamine agonist LEDD (F2,134=2.6; P=.08), but pergolide-treated patients were more likely to be taking a dopamine agonist LEDD of 500 mg/d or higher (Fisher exact test, P=.002).

**FREQUENCY OF ICDs**

Twenty-one patients screened positive for an ICD during PD, but 2 patients did not meet MIDI criteria for an ICD and 1 other could not be reached for follow-up. The frequencies of 1 or more ICDs were 4.0% (n=11) for an active ICD and 6.6% (n=18) for anytime during PD. Of patients with an active ICD, the problem was documented in their clinical record in 3 cases (27.3%).
Compulsive sexual behavior was as common as compulsive gambling among both active cases (2.6% [n = 7] vs 2.2% [n = 6], respectively) and those with an ICD anytime during PD (2.6% [n = 7] vs 2.6% [n = 7], respectively). The frequency of compulsive buying was 0.4% (n = 1) for active cases and 1.5% (n = 4) for anytime during PD.

Thirteen subjects reported a history of ICD symptoms prior to PD onset, including 5 of the 18 subjects with an ICD some time during the course of PD. For these 5 subjects, their ICD behavior during the course of PD was the same as the behavior exhibited prior to PD onset (3 cases of compulsive sexual behavior and 1 case each of compulsive gambling and buying).

DEMORAPHIC AND CLINICAL CORRELATES

On univariate analysis, younger age, longer PD duration, history of ICD symptoms prior to PD, and use of a dopamine agonist or amantadine were associated with the presence of an active ICD, with a suggestion for higher total LEDD (Table 1). All 11 active ICD cases were currently taking a dopamine agonist.

Examining the larger group of 18 patients who had experienced an ICD some time during the course of PD, all were taking a dopamine agonist while symptomatic. Based on the follow-up interview and review of medical records, 7 of them became asymptomatic either with discontinuation of dopamine agonist treatment (n = 4), a reduction in the dopamine agonist dosage (n = 2), or counseling (n = 1).

**EXACT LOGISTIC REGRESSION MODEL**

Based on the univariate results, age, PD duration, history of ICD symptoms prior to development of PD, dopamine agonist or amantadine use, and total LEDD met criteria to enter the multivariate model. In this model, dopamine agonist use and history of ICD symptoms prior to PD were the only significant predictors of an active ICD (Table 2).

**SPECIFIC DOPAMINE AGONISTS**

At screening, approximately half of patients with PD were taking a dopamine agonist (Table 3). Pramipexole was most frequently prescribed (33.3% of dopamine agonist use), followed by ropinirole (35.8%) and pergolide (10.9%). There were no differences between the 3 dopamine agonists in their association with ICDs (Fisher exact test, P = .21). Examining the larger group of patients who had experienced an ICD some time during the course of PD, 8 were taking ropinirole; 7, pramipexole; and 3, pergolide, while symptomatic.

**DOPAMINE AGONIST DOSE**

Examining only patients currently taking a dopamine agonist, ICDs were associated with exposure to higher daily doses of pergolide (t13 = −3.38; P = .05) but not pramipexole (t13 = −2.14; P = .06) or ropinirole (t13 = −0.81; P = .40). Using LEDDs and examining the 3 dopamine agonists as a class, treatment with higher doses was associated with the presence of an ICD (t13 = −4.06; P = .001).

**COMMENT**

Estimated frequencies of compulsive gambling in PD range from 0.5% to 4.9%. Our frequency estimate for compulsive gambling (2.2% for active cases and 2.6% for anytime during PD) fell in the intermediate range of those previously reported. We may have underestimated the

---

**Table 1. Demographic and Clinical Correlates of ICDs**

<table>
<thead>
<tr>
<th>Variable</th>
<th>No Active ICD</th>
<th>Active ICD</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, y</td>
<td>68.6 (10.2)</td>
<td>59.5 (9.4)</td>
<td>.006§</td>
</tr>
<tr>
<td>Male, No. (%)</td>
<td>182 (69.7)</td>
<td>10 (90.9)</td>
<td>.18</td>
</tr>
<tr>
<td>Married, No. (%)</td>
<td>206 (79.2)</td>
<td>9 (81.8)</td>
<td>&lt;.99</td>
</tr>
<tr>
<td>Education, y</td>
<td>14.7 (3.0)</td>
<td>14.7 (3.1)</td>
<td>.98‡</td>
</tr>
<tr>
<td>PD duration, y</td>
<td>6.9 (5.8)</td>
<td>11.2 (7.5)</td>
<td>.044§</td>
</tr>
<tr>
<td>Levodopa dosage, mg/d</td>
<td>448.1 (335.2)</td>
<td>543.6 (463.5)</td>
<td>.49‡</td>
</tr>
<tr>
<td>Total LEDD, mg/d</td>
<td>569.3 (369.1)</td>
<td>925.5 (534.9)</td>
<td>.04‡§</td>
</tr>
<tr>
<td>Dopamine agonist use, No. (%)</td>
<td>126 (48.3)</td>
<td>11 (100.0)</td>
<td>&lt;.001§</td>
</tr>
<tr>
<td>Amantadine use, No. (%)</td>
<td>49 (18.8)</td>
<td>6 (54.5)</td>
<td>.01§</td>
</tr>
<tr>
<td>MMSE score</td>
<td>28.3 (2.0)</td>
<td>28.6 (1.4)</td>
<td>.96†</td>
</tr>
<tr>
<td>GDS score</td>
<td>4.0 (3.0)</td>
<td>6.0 (5.5)</td>
<td>.26†</td>
</tr>
<tr>
<td>ICD behavior prior to PD, No. (%)</td>
<td>9 (3.5)</td>
<td>4 (36.4)</td>
<td>&lt;.001§</td>
</tr>
</tbody>
</table>

**Table 2. Exact Logistic Regression Model**

<table>
<thead>
<tr>
<th>Variable</th>
<th>Crude Adjusted</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>0.21 (0.02-1.04)</td>
</tr>
<tr>
<td>PD duration</td>
<td>3.03 (0.71-18.10)</td>
</tr>
<tr>
<td>Total LEDD†</td>
<td>1.84 (0.46-8.79)</td>
</tr>
<tr>
<td>Dopamine agonist use</td>
<td>16.27 (2.61‡)</td>
</tr>
<tr>
<td>Amantadine use#</td>
<td>5.15 (1.25-22.26¶)</td>
</tr>
<tr>
<td>ICD behavior prior to PD</td>
<td>15.54 (2.83-76.16¶)</td>
</tr>
</tbody>
</table>

Abbreviations: CI, confidence interval; LEDD, levodopa-equivalent daily dose; OR, odds ratio; PD, Parkinson disease.

*Adjusted values are adjusted for other 5 variables.
†LEDD for dopamine agonists + levodopa from other medications.
‡Upper boundary approaches infinity.
¶Median unbiased estimate owing to boundary.
#Amantadine hydrochloride.
frequency of ICDs in our population, because patients may have been either hesitant to acknowledge symptoms or less likely to be present in the clinic and therefore unavailable for screening.

To our knowledge, there is no published literature on the estimated prevalence of other ICDs in PD. We found that compulsive sexual behavior was as common as compulsive gambling, though that may have been due to the predominance of men in our sample. Regardless, our findings are consistent with recent reports suggesting an association between dopamine agonist treatment and compulsive sexual behavior in PD.

Of the 6 potential risk factors for ICDs identified in preliminary analyses, only dopamine agonist treatment and a history of ICD symptoms prior to PD predicted presence of an active ICD in the multivariate model. Previous reporting of younger patients with PD being disproportionately affected with ICDs may reflect prescribing patterns (eg, older patients are less likely to be treated with a dopamine agonist). Our data suggest that a history of ICD symptoms prior to PD is the main demographic or clinical variable that predicts an increased risk for the development of an ICD in the setting of dopamine agonist treatment.

The risk associated with ICDs was specific to the dopamine agonist medication class. Although there was a suggestion on univariate analysis of an association between the total LEDD and ICDs, this relationship was no longer observed after controlling for dopamine agonist use. These results suggest a distinct mechanism of action, as opposed to an additive effect, for dopamine agonists in the development of ICDs.

Our findings did not support a differential association between specific dopamine agonists and ICDs, suggesting a class effect. Two case series implicated pramipexole as the agent most likely to cause an ICD, but neither accounted for the relative frequency of pramipexole use in comparison with other dopamine agonists. There is great variability in the dosing of dopamine agonists in PD. Using LEDDs to examine the 3 dopamine agonists as a class, ICD cases were treated with higher dopamine agonist doses. These findings are consistent with 2 case series suggesting that the greatest risk for ICDs may involve dopamine agonist doses at the high end of the therapeutic range. If true, that may help explain why the highest frequency of ICD cases, even though not statistically significant, was in pergolide-treated patients, because this group was more likely to receive doses at the upper end of the therapeutic range.

Limitations of our study include the following: (1) Our study population was not randomly chosen; (2) subjects came from 2 centers (including 1 veterans’ hospital) in 1 region of the country, limiting the generalizability of our findings; (3) the follow-up telephone interview to verify the history of ICD behaviors was conducted up to 15 months after the screening process, which may have affected the validity of the data; (4) no measures of PD severity, other than duration of illness, were available for analysis; (5) ICD status was determined through the use of the MIDI rather than formal diagnostic interviews, and determination of ICD symptoms prior to PD onset was based on the unstructured screening interview only; and (6) only 11 ICD cases were identified, limiting the conclusions that can be reached about the nature of the associations between dopamine agonist treatment and ICDs in PD. Multisite studies involving larger random samples of patients are needed to definitively determine the prevalence and clinical correlates of ICDs in PD.

Our findings highlight the importance of screening for a variety of ICDs in patients with PD treated with a dopamine agonist, particularly since only one quarter of active ICD cases in this study had been identified clinically. It is not known whether the risk for ICDs with exposure to this medication class is specific to patients with PD. As dopamine agonists are increasingly prescribed for other indications (eg, recent Food and Drug Administration approval of ropinirole for the treatment of restless legs syndrome), it will be important to assess the prevalence and risk for ICDs in other dopamine agonist–treated populations.

**Accepted for Publication:** February 16, 2006.

**Correspondence:** Daniel Weintraub, MD; 3535 Market St, Room 3003, Philadelphia, PA 19104 (weintrau@mail.med.upenn.edu).

**Financial Disclosure:** Drs Weintraub, Siderowf, Potenza, Duda, and Stern have served as consultants to Boehringer Ingelheim Pharmaceuticals, Inc. Dr Siderowf has received grant support from Boehringer Ingelheim Pharmaceuticals, Inc.

**Funding/Support:** This study was supported by grant K23MH067894 from the National Institute of Mental Health and by the Mental Illness Research, Education,
and Clinical Centers at the Philadelphia and West Haven Veterans Affairs Medical Centers.

Author Contributions: Dr Weintraub had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Weintraub and Stern. Acquisition of data: Weintraub, Goveas, Duda, and Stern. Analysis and interpretation of data: Weintraub, Siderowf, Potenza, Morales, Duda, Moberg, and Stern. Drafting of the manuscript: Weintraub, Potenza, and Duda. Critical revision of the manuscript for important intellectual content: Weintraub, Siderowf, Potenza, Goveas, Morales, Duda, Moberg, and Stern. Statistical analysis: Weintraub and Morales. Administrative, technical, and material support: Weintraub, Siderowf, Duda, Moberg, and Stern. Study supervision: Weintraub and Stern.

Acknowledgment: We acknowledge Donna Taraborelli, BA, Katherine Oehlberg, BA, and Kirsten Saboe, BA, for the collection of the data.

REFERENCES